Amylyx Pharmaceuticals, Inc.
AMLX
$3.63
-$0.045-1.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -665.00K | 416.00K | -1.02M | 88.64M | 108.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -665.00K | 416.00K | -1.02M | 88.64M | 108.45M |
| Cost of Revenue | -13.31M | 58.25M | 30.77M | 153.01M | 54.27M |
| Gross Profit | 12.65M | -57.83M | -31.79M | -64.37M | 54.18M |
| SG&A Expenses | 17.10M | 17.83M | 21.65M | 57.76M | 52.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 22.85M | -- | -- |
| Total Operating Expenses | 39.99M | 76.08M | 75.26M | 210.77M | 106.52M |
| Operating Income | -40.65M | -75.66M | -76.29M | -122.13M | 1.93M |
| Income Before Tax | -38.18M | -72.70M | -72.70M | -118.55M | 6.48M |
| Income Tax Expenses | -635.00K | -- | -- | 242.00K | 1.75M |
| Earnings from Continuing Operations | -37.55M | -72.70M | -72.70M | -118.79M | 4.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.55M | -72.70M | -72.70M | -118.79M | 4.73M |
| EBIT | -40.65M | -75.66M | -76.29M | -122.13M | 1.93M |
| EBITDA | -40.49M | -75.44M | -76.08M | -121.82M | 2.24M |
| EPS Basic | -0.55 | -1.07 | -1.07 | -1.75 | 0.07 |
| Normalized Basic EPS | -0.44 | -0.67 | -0.67 | -1.09 | -0.03 |
| EPS Diluted | -0.55 | -1.07 | -1.07 | -1.75 | 0.07 |
| Normalized Diluted EPS | -0.44 | -0.67 | -0.67 | -1.09 | -0.03 |
| Average Basic Shares Outstanding | 68.59M | 68.09M | 68.02M | 67.85M | 67.41M |
| Average Diluted Shares Outstanding | 68.59M | 68.09M | 68.02M | 67.85M | 69.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
